- Home
- ASBP vs ICU Comparison
ASBP vs ICU Comparison
Compare ASBP & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASBP
- ICU
- Stock Information
- Founded
- ASBP 2021
- ICU 2018
- Country
- ASBP United States
- ICU United States
- Employees
- ASBP N/A
- ICU N/A
- Industry
- ASBP Biotechnology: Pharmaceutical Preparations
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- ASBP Health Care
- ICU Health Care
- Exchange
- ASBP Nasdaq
- ICU Nasdaq
- Market Cap
- ASBP 18.9M
- ICU 15.9M
- IPO Year
- ASBP N/A
- ICU N/A
- Fundamental
- Price
- ASBP $0.24
- ICU $0.49
- Analyst Decision
- ASBP
- ICU
- Analyst Count
- ASBP 0
- ICU 0
- Target Price
- ASBP N/A
- ICU N/A
- AVG Volume (30 Days)
- ASBP 2.6M
- ICU 1.1M
- Earning Date
- ASBP 11-24-2025
- ICU 11-13-2025
- Dividend Yield
- ASBP N/A
- ICU N/A
- EPS Growth
- ASBP N/A
- ICU N/A
- EPS
- ASBP N/A
- ICU N/A
- Revenue
- ASBP N/A
- ICU $766,000.00
- Revenue This Year
- ASBP N/A
- ICU $820.00
- Revenue Next Year
- ASBP N/A
- ICU $63.37
- P/E Ratio
- ASBP N/A
- ICU N/A
- Revenue Growth
- ASBP N/A
- ICU N/A
- 52 Week Low
- ASBP $0.20
- ICU $0.31
- 52 Week High
- ASBP $15.80
- ICU $3.07
- Technical
- Relative Strength Index (RSI)
- ASBP 36.55
- ICU 34.34
- Support Level
- ASBP $0.32
- ICU $0.42
- Resistance Level
- ASBP $0.47
- ICU $0.60
- Average True Range (ATR)
- ASBP 0.06
- ICU 0.05
- MACD
- ASBP -0.01
- ICU -0.01
- Stochastic Oscillator
- ASBP 8.27
- ICU 26.02
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.